EN2020|News Releases

Media

Media

Home>Media_en
China Resources Pharmaceutical Ranks No.2 of Top 10 China Enterprises in the PRC Pharmaceutical Industry Again

Press time:2016-11-18From:CR Pharma [ Font:BigMediumSmall]

The “China ChemPharm Annual Summit 2016” which jointly organized by China Pharmaceutical Industry Association, China Association of Pharmaceutical Commerce, China Nonprescription Medicines Association and China Pharmaceutical Enterprises Development Promote Association was held in Wuhan, China on November 15th,2016. The “Excellent enterprises and brands in the PRC Chemical Pharmaceutical Industry of 2016” was released during the summit. China Resources Pharmaceutical (“CR Pharma”) ranks 2nd on “Top 10 China Enterprises in the PRC Chemical Pharmaceutical Industry of 2016” listing.

CR Pharma’s subsidiaries, including CR Double-Crane, CR Zizhu and CR Saike were all listed on the “Top 100 Enterprises in the PRC Chemical Pharmaceutical Industry of 2016”, which ranks 21st, 73rd and 79th respectively. “Compound Dexamethasone Acetate Cream (Pi Yan Ping)” from CR Sanjiu continually won the “Excellent OTC brand in PRC Chemical Pharmaceutical Industry” award. At the same time, “Pitavastatin Calcium Tablets (Guan Shuang)”, “Levofloxacin” ,“Sodium Chloride Injection (Ying Yuan)”, “ Gliquidone” and basic injection products from CR Double-Crane, “Amlodipine Besylate Tablets (Ya Shi Da)” and “Valsartan Capsules (Hui Yue)” from CR Saike, “Levonorgestrel  Tablets (Yu Ting)” and “Jin Yuting” from CR Zizhu won the awards of “Excellent Brand”.

The theme of the summit this year was “Quality, Integrity and Brand”. The summit was a great opportunities for deep communication between Chemical Pharmaceutical enterprises in terms of understanding national relevant policies, analyzing pharmaceutical economic trend and publishing construction of drug traceability system, credit evaluation of pharmaceutical enterprises and etc.

CR Pharma will continue to pursue strategic acquisitions and to focus on research and innovation to further upgrade core competitiveness, to consolidate the leadership positions in the pharmaceutical industry and to provide high quality products and high value services to customers.

Prev | Next
Back to Top